As the FDA considers approval of psychedelic medicine within the U.S. health care system, it is imperative that we think about how people on Medicaid may (or may not) get access to these breakthrough therapies. We are pleased to respond to the Health Resources and Services Administration’s request for information about training and care models, and to share what we are learning with our partners working in the field.
With special thanks to Tanya Shah for pulling it all together into a coherent message about the work ahead and the role that HRSA can play to promote safe, affordable, and accessible psychedelic care.